Terms: = Breast cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Treatment
35401 results:
1. Metastasis diagnosis using attenuated total reflection-Fourier transform infra-red (ATR-FTIR) spectroscopy.
Abuh SO; Barbora A; Minnes R
PLoS One; 2024; 19(5):e0304071. PubMed ID: 38820279
[TBL] [Abstract] [Full Text] [Related]
2. [Anti-tumor mechanism of total saponins of Paridis Rhizoma on inducing ferroptosis of breast cancer MCF-7 cells].
Zhang YB; Zhang HZ; Ruan YD; Zhang YQ; Zhang PZ; Yao AN; Li SM; Xu XH; Ni J; Dong XX
Zhongguo Zhong Yao Za Zhi; 2024 May; 49(9):2385-2392. PubMed ID: 38812139
[TBL] [Abstract] [Full Text] [Related]
3. Anti-metastasis activity of 5,4'-dihydroxy 6,8-dimethoxy 7-O-rhamnosyl flavone from Indigofera aspalathoides Vahl on breast cancer cells.
Al-Saeedi F; Rajendran P
Sci Rep; 2024 May; 14(1):12349. PubMed ID: 38811791
[TBL] [Abstract] [Full Text] [Related]
4. Perceived barriers and factors influencing uptake of breast cancer screening among women: a population-based cross-sectional study.
Joho AA; Mdoe MB; Masoi TJ; Yahaya JJ
Sci Rep; 2024 May; 14(1):12291. PubMed ID: 38811672
[TBL] [Abstract] [Full Text] [Related]
5. Barriers to cancer treatment for people experiencing socioeconomic disadvantage in high-income countries: a scoping review.
Bourgeois A; Horrill T; Mollison A; Stringer E; Lambert LK; Stajduhar K
BMC Health Serv Res; 2024 May; 24(1):670. PubMed ID: 38807237
[TBL] [Abstract] [Full Text] [Related]
6. Patient preferences for breast cancer screening: a systematic review update to inform recommendations by the Canadian Task Force on Preventive Health Care.
Pillay J; Guitard S; Rahman S; Saba S; Rahman A; Bialy L; Gehring N; Tan M; Melton A; Hartling L
Syst Rev; 2024 May; 13(1):140. PubMed ID: 38807191
[TBL] [Abstract] [Full Text] [Related]
7. Oocyte collection and outcome following oncologic treatment: a retrospective multicentre study.
Fernández-González MJ; Borgmann-Staudt A; Llagostera CG; Ceballos-Garcia E; Gebauer J; Jantke A; Barnbrock A; Kentenich H; Klco-Brosius S; Lotz L; Balcerek M
Support Care Cancer; 2024 May; 32(6):390. PubMed ID: 38806697
[TBL] [Abstract] [Full Text] [Related]
8. Immune cell populations in the tumour environment following calcium electropora-tion for cutaneous metastasis: a histopathological study.
Vissing M; Sinius Pouplier S; Munch Larsen L; Krog Frandsen S; Lodin A; Lænkholm AV; Gehl J
Acta Oncol; 2024 May; 63():398-410. PubMed ID: 38804839
[TBL] [Abstract] [Full Text] [Related]
9. treatment of patients with carcinomas in advanced stages with 5-fluorouracil, folinic acid and pyridoxine in tandem.
Machover D; Almohamad W; Castagné V; Desterke C; Gomez L; Goldschmidt E
Sci Rep; 2024 May; 14(1):12054. PubMed ID: 38802419
[TBL] [Abstract] [Full Text] [Related]
10. Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis.
Dowling GP; Daly GR; Hegarty A; Hembrecht S; Bracken A; Toomey S; Hennessy BT; Hill ADK
Br J Surg; 2024 May; 111(5):. PubMed ID: 38801441
[TBL] [Abstract] [Full Text] [Related]
11. Non-metastatic primary neuroendocrine neoplasms of the breast: a reference cancer center's experience of a heterogenous entity.
Püsküllüoğlu M; Grela-Wojewoda A; Ambicka A; Pacholczak-Madej R; Pietruszka A; Mucha-Małecka A; Rudzińska A; Ziobro M; Ryś J; Mituś JW
Front Endocrinol (Lausanne); 2024; 15():1217495. PubMed ID: 38800480
[TBL] [Abstract] [Full Text] [Related]
12. Olsalazine pretreatment augments chemosensitivity of gemcitabine in hepatocellular carcinoma.
Sharma A; Chhipa AS; Verma S; Parikh P; Patel S
J Biochem Mol Toxicol; 2024 Jun; 38(6):e23737. PubMed ID: 38798245
[TBL] [Abstract] [Full Text] [Related]
13. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-breast03 trial.
Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
[TBL] [Abstract] [Full Text] [Related]
14.
Fei F; Caporale C; Chang L; Fortini BK; Ali H; Bell D; Stein A; Marcucci G; Telatar M; Afkhami M
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791222
[No Abstract] [Full Text] [Related]
15. Label-free electrochemical biosensor based on green-synthesized reduced graphene oxide/Fe
Hosseine M; Naghib SM; Khodadadi A
Sci Rep; 2024 May; 14(1):11928. PubMed ID: 38789508
[TBL] [Abstract] [Full Text] [Related]
16. Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
Khoirunnisa SM; Suryanegara FDA; Setiawan D; Postma MJ; de Jong LA
PLoS One; 2024; 19(5):e0304483. PubMed ID: 38787899
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes.
Chen L; Yan X; Luo T; Tian T; He P; Zhong X
Cancer Med; 2024 May; 13(10):e7295. PubMed ID: 38785215
[TBL] [Abstract] [Full Text] [Related]
18. Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
Lambert V; Kane S; Howidi B; Nguyen BN; Chandiwana D; Wu Y; Edwards M; Samjoo IA
BMC Cancer; 2024 May; 24(1):631. PubMed ID: 38783218
[TBL] [Abstract] [Full Text] [Related]
19. Prognosis and influencing factors of ER-positive, HER2-low breast cancer patients with residual disease after neoadjuvant chemotherapy: a retrospective study.
Tang L; Jiang L; Shu X; Jin Y; Yu H; Liu S
Sci Rep; 2024 May; 14(1):11761. PubMed ID: 38783028
[TBL] [Abstract] [Full Text] [Related]
20. cancer treatment Before and After Physician-Pharmacy Integration.
Kanter GP; Ozluk P; Chi W; Fisch MJ; Debono D; Parikh RB; Jacobson M; Bekelman JE; DeVries A
JAMA Netw Open; 2024 May; 7(5):e2412998. PubMed ID: 38780938
[TBL] [Abstract] [Full Text] [Related]
[Next]
